PNC Financial Services Group’s Stoke Therapeutics STOK Stock Holding History

PNC Financial Services Group’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$338	Sell	13 -31	-70%	-$936	﹤0.01%	5195
2026 Q2	$1.44K	Hold	44	–	–	﹤0.01%	4763
2026 Q1	$1.43K	Hold	44	–	–	﹤0.01%	4673
2025 Q4	$1.4K	Hold	44	–	–	﹤0.01%	4615
2025 Q3	$1.03K	Hold	44	–	–	﹤0.01%	4670
2025 Q2	$499	Hold	44	–	–	﹤0.01%	4686
2025 Q1	$293	Buy	44 +34	+340%	+$317	﹤0.01%	4731
2024 Q4	$110	Hold	10	–	–	﹤0.01%	4704
2024 Q3	$123	Hold	10	–	–	﹤0.01%	4713
2024 Q2	$135	Buy	10 +5	+100%	+$68	﹤0.01%	4704
2024 Q1	$68	Hold	5	–	–	﹤0.01%	4657
2023 Q4	$26	Buy	+5	New	+$21	﹤0.01%	4593

Other funds holding STOK

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

PNC Financial Services Group's STOK Position: Q3 2026 in Review

PNC Financial Services Group reduced its Stoke Therapeutics (STOK) stake by 70% in Q3 2026, selling an estimated $936 and leaving 13 shares worth $338. The position accounts for ﹤0.01% of the portfolio, ranked #5195.

PNC Financial Services Group first reported a position in STOK in Q4 2023 and has held it in 12 quarters since. The position peaked at $1.44K in Q2 2026. 74 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

PNC Financial Services Group held 13 shares of Stoke Therapeutics worth $338 as of Q3 2026.
PNC Financial Services Group sold 31 Stoke Therapeutics shares in Q3 2026, an estimated $936.
Stoke Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #5195 holding.
PNC Financial Services Group first reported a position in Stoke Therapeutics in Q4 2023 and has held it in 12 quarters since.
PNC Financial Services Group's Stoke Therapeutics position peaked at $1.44K in Q2 2026.
74 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.